DiaSorin stock
Price history
+32.38% over the period1 year: from €58.80 (November 20, 2025) to €77.84 (November 20, 2026), +32.38%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €77.84 |
| October 30, 2026 | €80.56 |
| September 30, 2026 | €76.80 |
| August 31, 2026 | €75.88 |
| July 31, 2026 | €71.86 |
| June 30, 2026 | €67.76 |
| May 29, 2026 | €66.52 |
| April 30, 2026 | €58.02 |
| March 31, 2026 | €59.98 |
| February 27, 2026 | €71.20 |
| January 30, 2026 | €72.18 |
| December 30, 2025 | €68.62 |
| November 28, 2025 | €61.78 |
| November 20, 2025 | €58.80 |
At a glance
The company
Develop, manufacture and distribute immunodiagnostic and molecular diagnostic testing kits for infectious diseases, endocrinology, oncology and other medical areas
Latest results
Quarter to June 30, 2026 · EPS €1.04 (estimate €1.00)
TickerLandia's take on DiaSorin
- Priced as usual relative to earnings: P/E on the latest fiscal year 27 vs a median of 30 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 29 vs 29 (+0%) in a group of 11.
- Strong point: Market momentum (81/100 in its group). Weak point: Growth (33/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−9.30% from the 52-week high
Analysts · 14 analysts
Average target€80.14+2.96% vs. price
Buy 5 · Hold 4 · Sell 5 · Hold
TickerLandia Fingerprint: DiaSorin
Compared with similar companies: very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow31
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 3.18 39 P/E (trailing 12 months) 28.6 31 EV/EBITDA 12.6 30 Price/book 2.63 25 Forward P/E 17.9 30 Profitabilityhigh61
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 64.6% 76 Net margin 12.0% 61 ROA 6.8% 65 ROE 9.2% 33 Operating margin 22.3% 72 Earnings stabilityaverage44
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 6.0% 28 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthlow33
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +6.56% 22 Average revenue growth (3 years) −4.24% 9 Revenue growth (year over year) +10.00% 67 Financial strengthaverage57
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.69 62 Current ratio 1.79 54 Interest coverage 11.7 63 Debt/equitycounts in reverse: lower means more financial strength 0.53 50 Dividendhigh68
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.7% 77 Payout ratio 47.8% 66 Consecutive dividend years at least 19 years 62 Market momentumvery strong81
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +32.38% 79 Relative strength (3 months) +12.65% 83 Relative strength (6 months) +16.00% 82 Distance from 200-day average +10.05% 80 Risklow34
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 26.8% 58 Volatility (60 days) 23.9% 35 Beta (1 year) 0.22 8
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
DiaSorin is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2025), DiaSorin's P/E today is 27.3, in line with the median of its last 10 fiscal years (30.3; between 24.1 and 37.8 from 2016 to 2025). DiaSorin's P/E (trailing 12 months): 28.6, in line with the median of a group of 11 similar companies (28.6).
Compared with 11 similar companies
| Metric | DiaSorin | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 28.6 | Middle | |
| Forward P/E | 17.9 | Middle | |
| Operating margin | 22.3% | Middle | |
| ROE | 9.2% | Middle | |
| Debt/equity | 0.53 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: DiaSorin. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€314.62M
Latest quarter · Q2 2026
Net income
€46.35M
Latest quarter · Q2 2026
Quarterly net margin
14.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €3.83B
- P/E
- 28.6
- EPS
- €2.72
- Volume
- 114.94K
- Daily trading
- €11.01M
- Dividend yield
- 1.67%
- Last ex-dividend on May 18, 2026
How DiaSorin is changing
All resultsRevenue grew 6.3% a year on average over the last 5 years
Operating margin fell from 27.5% to 23.0%
Profits turn into cash: free cash flow equal to 170% of net income
Returns
DiaSorin returns with dividends
€1,000 invested in DiaSorin 5 years ago, on November 22, 2021, would be worth €451 today with dividends reinvested: −54.90% in total, −14.74% per year. On price alone it would be €424 (−57.62%).
| Period | DiaSorin | FTSE MIB | €1,000 becomes |
|---|---|---|---|
| 1 month | −2.09% | −0.75% | €979 |
| 6 months | +14.88% | −0.97% | €1,149 |
| Year to date | +13.44% | +8.36% | €1,134 |
| 1 year | +34.82% | +13.48% | €1,348 |
| 3 years | −8.21% | +64.86% | €918 |
| 5 years | −54.90% | +77.86% | €451 |
| 10 years | +71.38% | +198.85% | €1,714 |
Over the last 6 months it has done better than 47% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment
The chart in detail
DiaSorin: technical analysis
DiaSorin shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 62.8% below its all-time closing high (€209.40, May 25, 2020).
- Trend
- No clear trend
- RSI (14 sessions)
- 41
- Between 30 and 70
- vs 200-session average
- +10.05%
Active signals
Close below the low of the previous 20 sessions.
Support and resistance
Price areas where DiaSorin has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€79.45+2.07%3 touches, last on November 6, 2026
- Last price€77.84
- Support€77.57−0.35%2 touches, last on August 28, 2026
- Support€76.18−2.13%5 touches, last on October 19, 2026
- Support€72.37−7.03%5 touches, last on October 2, 2026
Volatility and risk
Over the last year it has moved little with the FTSE MIB.
- Beta (1 year) vs FTSE MIB
- 0.22
- Volatility (60 sessions, annualised)
- 23.9%
- Largest fall in the last year
- −26.80%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
DiaSorin: seasonality
Average monthly price change over 20 years
Over the last 20 years, the strongest month for DiaSorin has been May: +4.90% on average, positive in 16 years out of 19. The weakest has been September: −1.01% on average, positive in 8 years out of 20. November, the current month, has been positive in 8 years out of 19 (−0.29% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.75% | +0.10% | 10 of 19 |
| February | +0.16% | −1.36% | 9 of 19 |
| March | −0.57% | −0.68% | 8 of 19 |
| April | +1.76% | +0.93% | 12 of 19 |
| May | +4.90% | +4.85% | 16 of 19 |
| June | +1.89% | −0.55% | 8 of 19 |
| July | +2.88% | +3.23% | 13 of 19 |
| August | +1.04% | +1.14% | 12 of 20 |
| September | −1.01% | −1.13% | 8 of 20 |
| October | +1.83% | +3.64% | 12 of 20 |
| November | −0.29% | −2.17% | 8 of 19 |
| December | +0.21% | −0.39% | 9 of 19 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
DiaSorin and its competitors
With 3,212 employees and sales of 1.2 billion euros in the fiscal year ended December 2025, the company develops, makes and distributes diagnostic test kits for clinical laboratories. Its immunoassay menu covers infections, digestive disorders, hepatitis and retroviruses, hormones, metabolic conditions and tumor markers, run on its LIAISON instruments. Its molecular line includes a congenital cytomegalovirus kit that detects viral DNA in saliva and urine, a respiratory panel, a yeast blood culture assay and the xMAP multiplexing platform. Products are sold in Europe, North America and other international markets.
- Headquarters
- Saluggia, Italy
- Employees
- 3,212
- Founded
- 1968
- Chief executive
- Carlo Rosa
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DiaSorinDIA | $4.21B | 22.3% | 28.6 | +14.88% |
| QiagenQIA | $10.23B | 26.7% | 28.5 | +50.69% |
| bioMérieuxBIM | $11.82B | 16.0% | 23.4 | +25.67% |
| DiagnostykaDIA | $1.27B | 14.9% | 20.2 | −6.62% |
| Eurofins ScientificERF | $16.03B | 14.1% | 29.6 | +37.31% |
| Lonza GroupLONN | $54.2B | 23.5% | 43.2 | +32.22% |
Same industry or related industries, similar size. Compare DiaSorin with its competitors · Full profile
